Article Sidebar

PDF
Date Published: 19/02/2023
Abstract Views: 394
Views PDF: 212
DOI: https://doi.org/10.51298/vmj.v522i1.4279
Issue
Vol. 522 No. 1 (2023)
Section
Các bài báo
How to Cite
Đỗ, D. T., Đỗ, X. H., Phạm, T. N., Hà, T. Đông, Nguyễn, M. H., Nguyễn, T. T. T., Điêu, K. K., Nguyễn, T. T., & Đào, T. H. Y. (2023). TREATMENT OF NON-INVASIVE BLADDER CANCER: COMBINATION OF EN- BLOC RESECTION BLADDER TUMOR AND INTRAVESICAL GEMCITABINE : A CASE REPORT. Vietnam Medical Journal, 522(1). https://doi.org/10.51298/vmj.v522i1.4279

TREATMENT OF NON-INVASIVE BLADDER CANCER: COMBINATION OF EN- BLOC RESECTION BLADDER TUMOR AND INTRAVESICAL GEMCITABINE : A CASE REPORT

Duy Tùng Đỗ1,, Xuân Hùng Đỗ1, Thị Ngọc Phạm1, Tuấn Đông Hà1, Mạnh Hùng Nguyễn1, Thị Thu Thủy Nguyễn1, Khắc Kiên Điêu1, Thị Thúy Nguyễn1, Thị Hải Yến Đào1
1 Medical Center of Phu Ninh District, Phu Tho Province

Main Article Content

Abstract

Bladder cancer ranks 11th in incidence and 13th in mortality in both sexes, of which 75-85% is non-muscle invasice bladder cancer (NIMBC). En-bloc resection of bladder tumor (ERBT) in the treatment of bladder cancer without muscle invasion has many advantages such as satisfactory pathology, low tumor survival rate, the recurrence rate is lower than standard endoscopic resertion (Transurethral resection of bladder tumor). Gemcitabine intravessical pump after surgery is a safe therapy to reduce the risk of recurrence. In this article, we report the case of an 84 year old male patient, admitted to the hospital with symtoms of hematuria and dysuria. The patient then underwent endoscopy to enblock the bladder tumor combined with intravesical gemcitabine, followed up at the 9 month with no sign of recurrence.

Article Details

Keywords

Enblock, ERBT, Bladder tumor, gemcitabine

References

1. Nguyễn Phúc Cẩm Hoàng, Nguyễn Thanh Mộng, Trần Trọng Huân (2021), "Ưu điểm phương pháp cắt đốt nội soi lấy nguyên khối bướu bàng quang bằng điện lưỡng cực", Tạp chí y học TP Hồ Chí Minh, 25 (1) tr. 195-199.
2. M. Babjuk et al (2020), Non- muscle invasive Bladder cancer (TaT1 and CIS), EAU Guideline, pp. 22-28.
3. Team Edittorial (2021), "BCG or Gemcitabine for Bladder Cancer: When Should They Be Used?", Bladdercancernet.
4. Jun- Lin Lu et al (2020), "Efficacy of intravesical therapies on the prevention of recurrence and progression of non‐muscle‐invasive bladder cancer: A systematic review and network meta‐analysis", Cancer medicine, 9 (21) pp. 7800-7809.
5. Makito Miyake et al (2021), "Fluorescent cystoscopy-assisted en bloc transurethral resection versus conventional transurethral resection in patients with non-muscle invasive bladder cancer: study protocol of a prospective, open-label, randomized control trial (the FLEBER study)", Biomedcentral, pp 136 .
6. Massimiliano Creta et al (2022), "En-bloc Laser Resection of Bladder Tumors: Where Are We Now?", Journal of Clinical Medicine, 11(12) pp. 3463.
7. Rodolfo Hurle et al (2020), "Intravesical gemcitabine as bladder‐preserving treatment for BCG unresponsive non‐muscle‐invasive bladder cancer. Results from a single‐arm, open‐label study", BJUJ Compass, 1(4) pp. 126-132.
8. Slawomir Poletajew et al (2021), "En-bloc resection of urinary bladder tumour – a prospective controlled multicentre observational study", Video surgery and other miniinvasive techniques, 16(1) pp. 145-150.